<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CBM104542 xml ?>
<?FILEmain xml ?>
<?FILEga1 jpg ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEmmc1 pdf ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Biol Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Biol Med</journal-id>
    <journal-title-group>
      <journal-title>Computers in Biology and Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0010-4825</issn>
    <issn pub-type="epub">1879-0534</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8404035</article-id>
    <article-id pub-id-type="pii">S0010-4825(21)00336-X</article-id>
    <article-id pub-id-type="doi">10.1016/j.compbiomed.2021.104542</article-id>
    <article-id pub-id-type="publisher-id">104542</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Development and application of the ocular immune-mediated inflammatory diseases ontology enhanced with synonyms from online patient support forum conversation</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Pendleton</surname>
          <given-names>Samantha C.</given-names>
        </name>
        <email>SCP887@student.bham.ac.uk</email>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Slater</surname>
          <given-names>Karin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Karwath</surname>
          <given-names>Andreas</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="aff3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Gilbert</surname>
          <given-names>Rose M.</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">d</xref>
        <xref rid="aff5" ref-type="aff">e</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Davis</surname>
          <given-names>Nicola</given-names>
        </name>
        <xref rid="aff6" ref-type="aff">f</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Pesudovs</surname>
          <given-names>Konrad</given-names>
        </name>
        <xref rid="aff7" ref-type="aff">g</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Liu</surname>
          <given-names>Xiaoxuan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="aff8" ref-type="aff">h</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Denniston</surname>
          <given-names>Alastair K.</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="aff3" ref-type="aff">c</xref>
        <xref rid="aff8" ref-type="aff">h</xref>
      </contrib>
      <contrib contrib-type="author" id="au9">
        <name>
          <surname>Gkoutos</surname>
          <given-names>Georgios V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="aff3" ref-type="aff">c</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au10">
        <name>
          <surname>Braithwaite</surname>
          <given-names>Tasanee</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="aff9" ref-type="aff">i</xref>
        <xref rid="aff10" ref-type="aff">j</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <aff id="aff1"><label>a</label>Institute of Cancer and Genomic Sciences, University of Birmingham, UK</aff>
      <aff id="aff2"><label>b</label>University Hospitals Birmingham NHS Foundation Trust, UK</aff>
      <aff id="aff3"><label>c</label>Health Data Research, UK</aff>
      <aff id="aff4"><label>d</label>Moorfields Eye Hospital NHS Foundation Trust, London, UK</aff>
      <aff id="aff5"><label>e</label>Institute of Ophthalmology, University College London, UK</aff>
      <aff id="aff6"><label>f</label>Olivia's Vision, Southampton Buildings, London, UK</aff>
      <aff id="aff7"><label>g</label>School of Optometry and Vision Science, University of New South Wales, Australia</aff>
      <aff id="aff8"><label>h</label>Institute of Inflammation and Ageing, University of Birmingham, UK</aff>
      <aff id="aff9"><label>i</label>Institute of Applied Health Research, University of Birmingham, UK</aff>
      <aff id="aff10"><label>j</label>The Medical Eye Unit, St Thomas' Hospital NHS Foundation Trust, London, UK</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author. Institute of Cancer and Genomic Sciences, University of Birmingham, UK. <email>SCP887@student.bham.ac.uk</email></corresp>
      <fn id="fn1">
        <label>1</label>
        <p id="ntpara0010">Joint last author.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>1</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
    <pub-date pub-type="ppub">
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <volume>135</volume>
    <elocation-id>104542</elocation-id>
    <history>
      <date date-type="received">
        <day>19</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>27</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>30</day>
        <month>5</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Authors</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <sec>
        <title>Background</title>
        <p>Unstructured text created by patients represents a rich, but relatively inaccessible resource for advancing patient-centred care. This study aimed to develop an ontology for ocular immune-mediated inflammatory diseases (OcIMIDo), as a tool to facilitate data extraction and analysis, illustrating its application to online patient support forum data.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p>We developed OcIMIDo using clinical guidelines, domain expertise, and cross-references to classes from other biomedical ontologies. We developed an approach to add patient-preferred synonyms text-mined from oliviasvision.org online forum, using statistical ranking. We validated the approach with split-sampling and comparison to manual extraction. Using OcIMIDo, we then explored the frequency of OcIMIDo classes and synonyms, and their potential association with natural language sentiment expressed in each online forum post.</p>
      </sec>
      <sec>
        <title>Findings</title>
        <p>OcIMIDo (version 1.2) includes 661 classes, describing anatomy, clinical phenotype, disease activity status, complications, investigations, interventions and functional impacts. It contains 1661 relationships and axioms, 2851 annotations, including 1131 database cross-references, and 187 patient-preferred synonyms. To illustrate OcIMIDo's potential applications, we explored 9031 forum posts, revealing frequent mention of different clinical phenotypes, treatments, and complications. Language sentiment analysis of each post was generally positive (median 0.12, IQR 0.01–0.24). In multivariable logistic regression, the odds of a post expressing negative sentiment were significantly associated with first posts as compared to replies (OR 3.3, 95% CI 2.8 to 3.9, p &lt; 0.001).</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p>We report the development and validation of a new ontology for inflammatory eye diseases, which includes patient-preferred synonyms, and can be used to explore unstructured patient or physician-reported text data, with many potential applications.</p>
      </sec>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical abstract</title>
      <p>
        <fig id="undfig1" position="anchor">
          <alt-text id="alttext0010">Image 1</alt-text>
          <graphic xlink:href="ga1"/>
        </fig>
      </p>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">Here we present OcIMIDo, the first ontology of its kind in ophthalmology.</p>
          </list-item>
          <list-item id="u0015">
            <label>•</label>
            <p id="p0015">We developed the ontology using domain expertise and clinical guidelines.</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">Novel synonym extraction method with tf-idf to capture patient voice.</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">Facilitates analysis of unstructured text relating to ocular inflammatory diseases.</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>Uveitis</kwd>
      <kwd>Ontology</kwd>
      <kwd>Inflammation</kwd>
      <kwd>Patient voice</kwd>
      <kwd>Sentiment</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0030">There is growing recognition of the discordance between patient and clinician priorities and perspectives, and the vital importance of integrating the ‘patient voice’ into research and clinical practice [<xref rid="bib1" ref-type="bibr">1</xref>]. Online patient-reported social media posts, tweets and blogs add a new dimension to the data landscape, and represent a rich, underutilised resource for advancing patient-centred care [<xref rid="bib1" ref-type="bibr">1</xref>]. However, unstructured text data, and especially text using patient-preferred phrases and terms, rather than formal clinical vocabulary, are relatively inaccessible to extraction and analysis.</p>
    <p id="p0035">Ontologies have been proposed, and demonstrated with great success, to address the challenge presented by unstructured text data [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>]. Ontologies serve as a computational knowledge representation framework, describing the semantics of biomedical concepts (e.g. clinical phenotypes, clinical signs, complications, investigations, and treatments). Within ontologies these concepts are standardised, and their hierarchy and logical relations facilitate data integration and knowledge sharing [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. In the context of text data, the labels of ontology classes and relations enable access to data or text tagged by them; the classes or relations associated with these labels can be employed to identify potential associations within text descriptions. For this purpose, multiple powerful computational tools have been developed within the biomedical research domain. Used alongside natural language processing (NLP) tools, ontologies facilitate simultaneous, systematic search, tagging and integration of unstructured text data records for all the items (‘classes’) they contain [<xref rid="bib6" ref-type="bibr">6</xref>]. By encoding specific types of relationships between classes, Machine Learning (ML) and predictive modelling applications can be facilitated [<xref rid="bib6" ref-type="bibr">6</xref>]. Ontology-guided ML approaches have, in some cases, been shown to achieve better performance than those that do not [<xref rid="bib7" ref-type="bibr">7</xref>].</p>
    <sec id="sec1.1">
      <label>1.1</label>
      <title>Literature review and objectives</title>
      <p id="p0040">There are hundreds of biomedical ontologies, several in widespread use (see <xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref>) [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>]. Within the medical domain, there is a long history of efforts to systematically represent knowledge across biomedicine (for example medications, procedures, primary and secondary health records etc). Some notable examples include the Unified Medical Language System (UMLS) [<xref rid="bib16" ref-type="bibr">16</xref>], The International Classification of Diseases (ICD) codes [<xref rid="bib17" ref-type="bibr">17</xref>] the UK Read codes [<xref rid="bib18" ref-type="bibr">18</xref>] and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) [<xref rid="bib19" ref-type="bibr">19</xref>]. Although, typically, medical terminologies were not originally designed and intended to be used as ontologies, they are hierarchically structured, and have recently adopted formal descriptions and axioms that cater to ontological operations and applications. While each of these ontologies include some classes relevant to a given disease area, rarely they comprehensively define all the important clinical concepts needed for meaningful application in relation to a particular disease and its presentation, investigation, diagnosis, management and impacts. Additionally, recent research has identified an unmet need for biomedical ontologies to also capture synonyms and abbreviations frequently used by patients and physicians [<xref rid="bib20" ref-type="bibr">20</xref>]. There is a lack of previous research exploring curation of lay synonyms from patient-generated text although one study used word2vec for synonym extraction from a Wikipedia corpus [<xref rid="bib21" ref-type="bibr">21</xref>].</p>
    </sec>
    <sec id="sec1.2">
      <label>1.2</label>
      <title>Aims</title>
      <p id="p0045">Inflammatory eye diseases, including the clinical phenotypes of uveitis, scleritis and optic neuritis, is important because it is sight-threatening, adversely impact quality of life, typically are present throughout the life course, have associations with multi-organ immune-mediated inflammatory diseases of infectious and autoimmune aetiology [<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib23" ref-type="bibr">23</xref>] and often require systemic immunosuppressive or immunomodulatory therapy [<xref rid="bib24" ref-type="bibr">24</xref>].</p>
      <p id="p0050">The primary objective of this study was to report the development of a novel ontology that includes patient preferred terms, the ocular immune-mediated inflammatory diseases ontology (OcIMIDo). Secondary objectives were the application of the ontology to unstructured free text data in two online peer support fora for patients with inflammatory eye disease and their carers. First, we explored frequency of mention of ontology classes (e.g. anterior uveitis, rheumatoid arthritis, or use of methotrexate) in these fora using OcIMIDo and NLP approaches. Second, we performed an exploratory analysis for associations between the OcIMIDo classes and natural language sentiment analysis score at the level of an individual post, using two different sentiment analysis tools, to seek preliminary insight into the psychological impact of disease, medical therapies, and complications. Here we report the successful development, validation and application of OcIMIDo.</p>
    </sec>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Methods</title>
    <p id="p0055">The University of Birmingham Ethics Committee determined that approval was not required for this study (ERN_20–0047). The research adhered to the tenets of the Declaration of Helsinki.</p>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Development of a new ontology: OcIMIDo</title>
      <p id="p0060">Using Protégé, an open source ontology editor [<xref rid="bib25" ref-type="bibr">25</xref>], we created OcIMIDo in the Web Ontology Language (OWL) [<xref rid="bib26" ref-type="bibr">26</xref>]. Our initial foundation classes were extracted and extended by a clinician specialising in inflammatory eye disease, from The Royal College of Ophthalmologists Clinical Dataset (RCOphth) expert consensus document for uveitis [<xref rid="bib27" ref-type="bibr">27</xref>]. We added additional classes from five widely used biomedical ontologies, on 9th July 2019, via the Ontology Lookup Service [<xref rid="bib28" ref-type="bibr">28</xref>]. These were the Disease Ontology (DOID) [<xref rid="bib9" ref-type="bibr">9</xref>], the Human Phenotype Ontology (HPO) [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>], the Orphanet Rare Disease Ontology (ORDO) [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>], the Phenotype and Trait Ontology (PATO) [<xref rid="bib6" ref-type="bibr">6</xref>], and the Uber-anatomy Ontology (UBERON) [<xref rid="bib15" ref-type="bibr">15</xref>]. We added their term identifiers as cross-reference annotations. We excluded classes that were not relevant to ocular inflammatory diseases (e.g. iris nevus [HP:0011525]). We added relationships using the Relation Ontology [<xref rid="bib14" ref-type="bibr">14</xref>]. Axioms were automatically populated from the inferred relations within the ontology structure, to include both equivalent class axioms (e.g. high intraocular pressure “Equivalent To” ocular hypertension), and disjointness axioms (e.g. anterior chamber cells grade 0 “Disjoint With” anterior chamber cells grade 1+). We added cross-references between classes and relevant SNOMED-CT [<xref rid="bib19" ref-type="bibr">19</xref>], ICD-10 [<xref rid="bib17" ref-type="bibr">17</xref>], and Read Code terms [<xref rid="bib18" ref-type="bibr">18</xref>], where these were available. Ontology concepts are fully defined in <xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>.</p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Extraction of data from online patient fora</title>
      <p id="p0065">We obtained permission to download and extract text from public online support fora of the UK-based “Olivia's Vision” (OV) charity [oliviasvision.org], and the USA-based, “The Ocular Immunology and Uveitis Foundation” (UVE) organization [uveitis.org]. We downloaded OV on 14 March 2019 and UVE on 6 October 2019, and parsed the fora text data with Python [<xref rid="bib29" ref-type="bibr">29</xref>], separately identifying threads and their posts, whilst maintaining the anonymity of users.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Patient-preferred synonyms</title>
      <p id="p0070">To identify patient-preferred terms in the OV forum and relate them to clinical terms in OcIMIDo, we used a novel NLP-guided curation technique. Treating each thread as a unique observation, we used equal frequency binning to divide the threads into three size classes (based on the number of posts each contained). To generate a stratified test set, we extracted a random 20% of threads for the test set and used the remaining 80% as the training set. Using the Natural Language Toolkit (NLTK) [<xref rid="bib30" ref-type="bibr">30</xref>], with each thread in the training set, we cleaned (pre-processed) each post into the same format: lowercase, removal of “stop words” (i.e. words that carry little meaning: “the”, “thanks”, “xx”), and stemming all words to standardise their format across threads (e.g. “pained”, “painful”, and “pains” all became “pain”).</p>
      <p id="p0075">To extract all informative terms from this forum, we proceeded in an iterative way: we added patient-preferred synonyms text-mined from the OV forum, using statistical ranking with the text feature extraction function, “term frequency–inverse document frequency” (tf-idf) in Scikit-learn [<xref rid="bib31" ref-type="bibr">31</xref>]. The tf-idf statistic is a numerical statistical technique which measures the information in a document and balances it based on size. We applied tf-idf on all documents in the training set, resulting in a word list where higher scores represented more informative words. A domain expert (TB) manually reviewed words scoring above 1.0 to identify meaningful synonyms and classes for inflammatory and infectious eye disease, which we added to OcIMIDo. At the end of this each round of tf-idf, we removed the added synonyms from the training set and re-ran the tf-idf analysis to reweigh remaining words. With the reweighted set, we again curated words identified to be meaningful synonyms and classes, and added these to the ontology. We repeated this process five times and then at the sixth round we identified no additional informative terms. We manually consolidated misspellings into correctly spelled terms during evaluation of tf-idf metrics at each stage.</p>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Validation</title>
      <p id="p0080">First, we performed a tf-idf analysis on the OV test set and manually compared informative words in the training and testing sets to identify any missed classes or synonyms, timing this activity. Second, we performed a tf-idf analysis on the USA-based UVE forum to identify any missed classes or synonyms. Third, two clinicians (RG and XL), not involved in developing the ontology, independently spent a timed 60-min period manually highlighting as many words of relevance to ocular IMID as possible. We compared the number of items identified to those identified by the tf-idf method. We explored differences, including time taken, between manual and tf-idf approaches, and extrapolated to obtain an estimate of the time it would take to manually identify words for inclusion in the ontology.</p>
    </sec>
    <sec id="sec2.5">
      <label>2.5</label>
      <title>Using OcIMIDo to explore unstructured text data</title>
      <p id="p0085">We explored the posts across the OV test set using the Stanford CoreNLP [<xref rid="bib32" ref-type="bibr">32</xref>] suite with the RegexNER annotator to tag named entities in the text. RegexNER added the concept identifiers (e.g. “blurred vision” and it's synonym “blurry” had the same identifier [OCIMIDO:00141]). We observed the frequency of classes (or their synonyms) across the training and testing posts. We repeated this approach to explore and tag the USA-based UVE forum.</p>
    </sec>
    <sec id="sec2.6">
      <label>2.6</label>
      <title>Application of OcIMIDo to sentiment analysis</title>
      <p id="p0090">We combined text data from the two fora, OV and UVE. Using TextBlob [<xref rid="bib33" ref-type="bibr">33</xref>] and VADER [<xref rid="bib34" ref-type="bibr">34</xref>], we obtained a natural language sentiment score for each post. Both are open source tools for sentiment analysis that use a lexicon-based method to estimate sentiment. An advantage of these tools is that they do not require any training data as they are pretrained models, developed using NLTK [<xref rid="bib30" ref-type="bibr">30</xref>], thus avoiding the time-consuming task of manually labelling data. Both have been widely used in sentiment analysis of online public free text data, such as research looking into Twitter posts for discussions about chemotherapy [<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib36" ref-type="bibr">36</xref>].</p>
      <p id="p0095">We performed exploratory statistical analyses using standard statistical software, Stata (release 13.1) [<xref rid="bib37" ref-type="bibr">37</xref>]. We sorted the data for each forum by sentiment score, for both TextBlob and VADER independently, and removed 50% from each, retaining only the most positive and most negative 25% of scores. We combined this data, and explored single and then multiple logistic regression models for the odds of a score in the most negative 25th percentile, by a range of clinically relevant potential predictor variables (e.g. different inflammatory subtypes, systemic disease associations, ocular complications, and treatments). We fitted a full exploratory multivariable logistic regression model containing variables with a global p-value of &lt; 0.1 in single variable analysis. We identified the most parsimonious model, which had the smaller value of the Akaike's Information Criterion (AIC) and the Bayesian Information Criterion (BIC), using a stepwise backward elimination approach. We measured the discriminative performance of each model using the area under the receiver operating characteristic curve (AUC). We obtained global p-values, using the likelihood ratio test (LRT). We took a p-value of 0.05 or lower to be statistically significant.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results</title>
    <sec id="sec3.1">
      <label>3.1</label>
      <title>OcIMIDo</title>
      <p id="p0100">OcIMIDo is open source and freely available via GitHub, accessible at <ext-link ext-link-type="uri" xlink:href="https://github.com/sap218/ocimido" id="intref0010">https://github.com/sap218/ocimido</ext-link>. We followed the MIRO guidelines for ontology reporting [<xref rid="bib38" ref-type="bibr">38</xref>]. OcIMIDo (version 1.2) contained 661 classes, with 210 classes extracted from the foundation document [<xref rid="bib27" ref-type="bibr">27</xref>], and a total of 1661 relationships (including axioms) (see <xref rid="fig1" ref-type="fig">Fig. 1</xref> created with WebVOWL [<xref rid="bib39" ref-type="bibr">39</xref>], and <xref rid="tbl1" ref-type="table">Table 1</xref>). There were 2851 annotations: 187 of these were synonyms from OV (e.g. generic, proprietary drug names, and commonly used abbreviations) and 1131 were cross-references (700 to medical ontologies, of which 398 were to SNOMED-CT).<fig id="fig1"><label>Fig. 1</label><caption><p>Graphical representation of the ocular immune-mediated inflammatory diseases ontology, with a close-up of systemic, non-infectious disease associations. Each node is a class (e.g. “multiple sclerosis”) and each edge is a relationship, with dotted lines defining “subclass of” and solid lines defining constructed relationships, labelled with boxes (e.g. “investigated by”).</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Examples of constructed relationship types contained in OcIMIDo.</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Relationship</th><th>Count</th><th>Cross-reference</th><th>Example</th><th>Notes about meaning</th></tr></thead><tbody><tr><td align="left">adjacent to</td><td align="left">62</td><td align="left">RO:0002220</td><td align="left">choroid is adjacent to the sclera</td><td align="left">Anatomical descriptor</td></tr><tr><td align="left">part of has part</td><td align="left">104</td><td align="left">BFO:0000050</td><td align="left">choroid is part of the uvea</td><td align="left">Anatomical descriptor (where the inverse is always true)</td></tr><tr><td align="left">characterised by</td><td align="left">20</td><td align="left">SCDO:0000662</td><td align="left">sarcoidosis is characterised by granulomatous histopathology</td><td align="left">Disease definition (unidirectional)</td></tr><tr><td align="left">investigated by investigation for</td><td align="left">84</td><td align="left">None applicable</td><td align="left">Reiter's investigated by HLA-B27</td><td align="left">Investigations included in Royal College of Ophthalmology Consensus document [24] (inverse is always true)</td></tr><tr><td align="left">is a</td><td align="left">657</td><td align="left">None applicable</td><td align="left">oral is a route of administration</td><td align="left">Defines what something is (unidirectional as it is defining subclass relations)</td></tr><tr><td align="left">occurs in</td><td align="left">57</td><td align="left">BFO:0000066</td><td align="left">retinitis occurs in the retina<break/>anti-viral is a treatment of viral infection</td><td align="left">Descriptor of pathology in relation to anatomy or life-course stage (unidirectional)</td></tr><tr><td align="left">treatment of</td><td align="left">16</td><td align="left">RO:0002606</td><td/><td align="left">(unidirectional)</td></tr></tbody></table></table-wrap></p>
      <p id="p0105">Each concept in OcIMIDo was assigned a unique identifier (e.g. uveitis [OCIMIDO_00213]). We used Protégé’s Pellet reasoner to ensure a coherent and consistent ontology. OcIMIDo had eight top-level classes, three of these included classification [OCIMIDO:00001], complications [OCIMIDO:00003], and therapeutic interventions [OCIMIDO:00004]. The top-level class, classification, included anatomical structure [OCIMIDO:00462], inflammatory disorder [OCIMIDO:00465], and symmetry [OCIMIDO:00306]. The other top-level class, therapeutic interventions [OCIMIDO:00004], contained types of therapy [OCIMIDO:00391], with subclasses of medical therapy [OCIMIDO:00020], and surgical therapy [OCIMIDO:00021]. <xref rid="appsec1" ref-type="sec">Supplementary Table 5</xref> summarises OcIMIDo class counts, cross-reference counts and synonym counts, from different sources. <xref rid="appsec1" ref-type="sec">Supplementary Table 6</xref> summarises OcIMIDo's frequency of different annotations (labels, comments, cross-references, sources from which data were extracted, synonyms, and sources of synonym extraction), and illustrates these annotations with respect to one disease, Vogt-Koyanagi-Harada disease [OCIMIDO:00108].</p>
    </sec>
    <sec id="sec3.2">
      <label>3.2</label>
      <title>Online data extracted from patient support fora</title>
      <p id="p0110">The OV forum contained 2176 posts on 14 March 2019, including 416 primary topic threads, with an average of 5.2 posts (standard deviation 3.9) per thread, ranging from 1 to 16. The UVE forum contained 6855 posts on 6 October 2019, split into 1488 primary topic threads, with an average of 4.6 posts (standard deviation 3.2) per thread, ranging from 0 to 10. Together there were 1904 threads and 9031 forum posts.</p>
    </sec>
    <sec id="sec3.3">
      <label>3.3</label>
      <title>Identifying patient preferred synonyms to add to OcIMIDo</title>
      <p id="p0115">The tf-idf analysis on the OV training set (334 threads/1731 posts/6032 words resulted in an additional 208 new terms for inclusion in the ontology (187 synonyms and 21 classes, taking less than 5-min to manually check the list of 653 ranked terms with scores &gt;1.0, and 30 min for all). Many words were considered irrelevant by the domain expert, for example, “time”, “day”, and “hospital”. Examples of words added as synonyms include, “drop”, “steroid”, “humira”, “flare”, “treatment”, and “pressure”.</p>
    </sec>
    <sec id="sec3.4">
      <label>3.4</label>
      <title>Validation</title>
      <p id="p0120">First, we repeated the tf-idf analysis on the test set (82 threads/428 posts in 0.6 s). The distribution of a selection of tagged OcIMIDo classes appears very similar in the training and test sets (see <xref rid="appsec1" ref-type="sec">Supplementary Fig. 3</xref>). For example, 74% of posts in both sets mentioned “uveitis”, 22% and 23% mentioned “corticosteroids” and 27% in both mentioned “methotrexate”. It took 13 min for the domain expert to review the first set of 2581 ranked terms, finding 46 new terms, of which 29 were not “new” synonyms and the other 17 included non-relevant terms. In total, using the tf-idf approach to identify classes and synonyms for inclusion in the ontology from all 2176 posts in OV, took 3 s of computer time, plus approximately 43-min of domain expert time to scan all 8613 terms. Second, tf-idf analysis on the full OV and UVE fora (12 s, identified that the only non-overlapping items were region-specific drug brand names, for example “xibrom”, which is a nonsteroidal anti-inflammatory drug used in North America.</p>
      <p id="p0125">Third, in a timed 60-min exercise, two clinicians, not involved in developing the ontology, independently manually highlighted as many words of relevance to ocular IMID as possible. Clinician one identified 103 unique terms in 376 posts, 54 of these were already included as classes and 30 were synonyms found in the tf-idf on the training set (19 remaining). Clinician two identified 100 unique terms in 69 posts, 37 of these were already classes and 20 were synonyms found in the tf-idf on the training set (43 remaining). Of the combined remaining 62 terms, only 10 terms overlapped. A third expert deemed only 6 additional terms were useful synonyms, these included, “attack”, “bouts”, and “blood shot”. Extrapolating, to explore and extract informative terms from all OV and UVE 9031 posts manually, we estimate it would take 24 h for clinician one, 131 h for clinician two, in comparison to 12.2 s for the tf-idf to run and 2 h for the domain expert to scan through 24,312 ranked terms. This illustrates that tf-idf analysis, with expert curation of a ranked list of items, can be a much faster approach for synonym retrieval when compared to a purely manual curation approach.</p>
    </sec>
    <sec id="sec3.5">
      <label>3.5</label>
      <title>The impact of synonym inclusion in ontology class mentions</title>
      <p id="p0130">Adding patient-preferred synonyms increased the number of posts identified to be relevant to the sentiment analysis on account of containing tagged classes. For example, using “methotrexate” with synonyms “mtx”, “mxt” [a common misspelling based on ranking], and “amethopterin” increased the post count by 80%, from 185 to 333; using “adalimumab” with synonym “humira” increased the post count by 3014%, from 7 to 218 (see <xref rid="appsec1" ref-type="sec">Supplementary Fig. 4</xref>).</p>
    </sec>
    <sec id="sec3.6">
      <label>3.6</label>
      <title>Annotating the fora data using OcIMIDo</title>
      <p id="p0135">Exploration of the 9014 posts from the two discussion/support fora provided insight into aspects of inflammatory eye disease and its management of interest or concern to the patients using these two patient support fora (See <xref rid="tbl2" ref-type="table">Table 2</xref> for illustrative selection). Discussion of the subtypes of inflammatory eye disease differed between OV and UVE. For example, anterior uveitis was mentioned by 5.7% (n = 124) OV posts and 8.4% (n = 577) UVE posts (p &lt; 0.001), optic neuritis was mentioned by no posts in OV but 1.0% (n = 70) in UVE, scleritis was mentioned in 0.1% (n = 2) OV posts and 2.7% (n = 184) UVE posts. Discussion of complications was frequent in both fora. For example, cataract was mentioned in 10.0% (n = 218) OV posts and 7.1%(n = 483) UV posts (p &lt; 0.001) and glaucoma was mentioned in 3.7% (n = 81) OV posts and 5.3%(n = 363) UV posts. Systemic diseases were also frequently mentioned. For example, Juvenile idiopathic arthritis was mentioned in 4.5% (n = 97) OV posts, and 1.5% (n = 105) UVE posts, p &lt; 0.001; whilst multiple sclerosis was mentioned in 0.4%(n = 8) OV posts and 1.7% (n = 119) UVE posts, p &lt; 0.001; and inflammatory bowel disease was mentioned in 0.5% (n = 11) OV posts and 2.2% (n = 152) UVE posts, p &lt; 0.001). Posts often included treatments being used or considered, and some differences may result from differences in treatment preferences and availability in the UK and USA. For example, adalimumab was mentioned in 10.0% (n = 218) OV posts and 7.2% (n = 495) UVE posts, p &lt; 0.001; mycophenolate mofetil was mentioned in 1.9% (n = 41) OV posts and 5.2% (n = 356) UVE posts, p &lt; 0.001). Newer biologic therapies, including ustekinumab, tocilizumab, certolizumab, had few mentions in either fora.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Illustration of the frequency count of a selection of some of the 661 OcIMIDo class items in the posts from the two patient fora.</p><p>*OR from Multivariable logistic regression model, also adjusted for first post (versus replies to a thread). Otherwise, odds ratios are for single variable analysis.</p><p>KEY: OV <ext-link ext-link-type="uri" xlink:href="http://oliviasvision.org" id="intref0085">oliviasvision.org</ext-link>; UVE <ext-link ext-link-type="uri" xlink:href="http://uveitis.org" id="intref0090">uveitis.org</ext-link>.</p></caption><alt-text id="alttext0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">OcIMIDo ontology class</th><th colspan="3">All posts (n = 9031)<hr/></th><th colspan="2">Most negative + positive 25th posts, Odds of post expressing negative sentiment OR (95% CI), p value<hr/></th></tr><tr><th>OV forum % (n)</th><th>UVE forum % (n)</th><th>Chi2 p value</th><th>TextBlob (n = 4480)</th><th>VADER (n = 4557)</th></tr></thead><tbody><tr><td colspan="6" align="left"><bold>Examples of some clinical phenotypes</bold></td></tr><tr><td align="left">Scleritis</td><td align="left">0.1 (2)</td><td align="left">2.7 (184)</td><td align="left">p &lt; 0.001</td><td align="left">1.9 (1.2–3.2), p = 0.007</td><td align="left">1.3 (0.9–1.9), p = 0.207</td></tr><tr><td align="left">Anterior uveitis</td><td align="left">5.7 (124)</td><td align="left">8.4 (577)</td><td align="left">p &lt; 0.001</td><td align="left">2.3 (1.7–3.1), p &lt; 0.001*</td><td align="left">1.3 (1.0–1.5), p = 0.027</td></tr><tr><td align="left">Intermediate uveitis</td><td align="left">1.8 (38)</td><td align="left">5.8 (397)</td><td align="left">p &lt; 0.001</td><td align="left">1.5 (1.0–2.1), p = 0.041</td><td align="left">0.8 (0.6–1.1), p = 0.145</td></tr><tr><td align="left">Macular oedema</td><td align="left">1.4 (31)</td><td align="left">2.1 (144)</td><td align="left">p = 0.046</td><td align="left">1.3 (0.7–2.4), p = 0.389</td><td align="left">0.5 (0.3–0.7), p = 0.001</td></tr><tr><td align="left">Posterior uveitis</td><td align="left">0.9 (20)</td><td align="left">2.6 (179)</td><td align="left">p &lt; 0.001</td><td align="left">1.4 (0.8–2.3), p = 0.263</td><td align="left">0.5 (0.3–0.7), p &lt; 0.001</td></tr><tr><td align="left">Panuveitis</td><td align="left">1.5 (32)</td><td align="left">1.7 (113)</td><td align="left">p = 0.565</td><td align="left">1.8 (1.0–3.5), p = 0.070</td><td align="left">0.6 (0.4–1.0), p = 0.036</td></tr><tr><td align="left">Optic neuritis<hr/></td><td align="left">0 (0)<hr/></td><td align="left">1.0 (70)<hr/></td><td align="left">p &lt; 0.001<hr/></td><td align="left">1.1 (0.5–2.2), p = 0.895<hr/></td><td align="left">0.9 (0.5–1.7), p = 0.829<hr/></td></tr><tr><td colspan="6" align="left"><bold>Examples of some associated systemic or neurological diseases</bold></td></tr><tr><td align="left">Ankylosing spondylitis</td><td align="left">0.7 (16)</td><td align="left">1.6 (109)</td><td align="left">p = 0.003</td><td align="left">1.3 (0.6–2.5), p = 0.515</td><td align="left">0.8 (0.5–1.3), p = 0.370</td></tr><tr><td align="left">Behcet's disease</td><td align="left">0.3 (7)</td><td align="left">1.3 (92)</td><td align="left">p &lt; 0.001</td><td align="left">0.7 (0.4–1.4), p = 0.290</td><td align="left">0.7 (0.4–1.2), p = 0.214</td></tr><tr><td align="left">Inflammatory bowel disease</td><td align="left">2.2 (152)</td><td align="left">0.5 (11)</td><td align="left">p &lt; 0.001</td><td align="left">1.3 (0.7–2.3), p = 0.351</td><td align="left">1.0 (0.6–1.4), p = 0.844</td></tr><tr><td align="left">Birdshot</td><td align="left">0.60 (13)</td><td align="left">1.01 (69)</td><td align="left">p = 0.080</td><td align="left">0.8 (0.3–1.7), p = 0.516</td><td align="left">0.4 (0.2–0.7), p = 0.001</td></tr><tr><td align="left">Juvenile idiopathic arthritis</td><td align="left">4.5 (97)</td><td align="left">1.5 (105)</td><td align="left">p &lt; 0.001</td><td align="left">1.7 (1.0–3.0), p = 0.052*</td><td align="left">0.6 (0.4–0.9), p = 0.017</td></tr><tr><td align="left">Multiple sclerosis</td><td align="left">0.4 (8)</td><td align="left">1.7 (119)</td><td align="left">p &lt; 0.001</td><td align="left">2.1 (1.0–4.2), p = 0.049</td><td align="left">1.0 (0.6–1.5), p = 0.842</td></tr><tr><td align="left">Psoriasis</td><td align="left">0.3 (7)</td><td align="left">1.7 (113)</td><td align="left">p &lt; 0.001</td><td align="left">0.9 (0.5–1.9), p = 0.813</td><td align="left">1.1 (0.7–1.8), p = 0.688</td></tr><tr><td align="left">Rheumatoid arthritis</td><td align="left">0.7 (16)</td><td align="left">1.1 (78)</td><td align="left">p = 0.107</td><td align="left">2.8 (1.1–7.2), p = 0.029*</td><td align="left">1.2 (0.7–2.1), p = 0.453</td></tr><tr><td align="left">Cat scratch disease</td><td align="left">1.0 (1)</td><td align="left">0.2 (8)</td><td align="left">p = 0.356</td><td align="left">8.2 (1.0–67.5), p = 0.050*</td><td align="left">1.2 (0.5–2.7), p = 0.702</td></tr><tr><td align="left">Sarcoidosis<hr/></td><td align="left">0.1 (1)<hr/></td><td align="left">0.3 (19)<hr/></td><td align="left">p = 0.046<hr/></td><td align="left">2.0 (0.4–10.7), p = 0.437<hr/></td><td align="left">0.5 (0.1–1.6), p = 0.244<hr/></td></tr><tr><td colspan="6" align="left"><bold>Examples of some ocular complications of disease or its treatment</bold></td></tr><tr><td align="left">Cataract</td><td align="left">10.0(218)</td><td align="left">7.1 (483)</td><td align="left">p &lt; 0.001</td><td align="left">1.6 (1.2–2.2), p = 0.003*</td><td align="left">1.5 (1.1–2.0), p = 0.018</td></tr><tr><td align="left">Glaucoma</td><td align="left">3.72 (81)</td><td align="left">5.3 (363)</td><td align="left">p = 0.003</td><td align="left">1.8 (1.3–2.5), p = 0.001</td><td align="left">1.3 (0.9–1.8), p = 0.231</td></tr><tr><td align="left">Epiretinal membrane</td><td align="left">0.28 (6)</td><td align="left">0.93 (65)</td><td align="left">p = 0.002</td><td align="left">2.7 (0.9–8.5), p = 0.089</td><td align="left">2.4 (0.7–8.0), p = 0.145</td></tr><tr><td align="left">Ocular Hypertension</td><td align="left">1.19 (26)</td><td align="left">0.53 (36)</td><td align="left">p = 0.001</td><td align="left">2.5 (1.0–6.4), p = 0.063</td><td align="left">0.2 (0.1–0.5), p = 0.238</td></tr><tr><td align="left">Retinal detachment<hr/></td><td align="left">0.6 (13)<hr/></td><td align="left">0.47 (32)<hr/></td><td align="left">p = 0.451<hr/></td><td align="left">1.0 (0.3–3.4), p = 0.975<hr/></td><td align="left">0.2 (0.1–0.5), p = 0.001<hr/></td></tr><tr><td colspan="6" align="left"><bold>Examples of some treatments</bold></td></tr><tr><td align="left">Oral prednisolone</td><td align="left">6.2 (135)</td><td align="left">4.8 (329)</td><td align="left">p = 0.010</td><td align="left">2.2 (1.5–3.4), p &lt; 0.001*</td><td align="left">1.3 (1.0–1.7), p = 0.040</td></tr><tr><td align="left">Intravitreal triamcinolone</td><td align="left">0.09 (2)</td><td align="left">0.64 (44)</td><td align="left">p = 0.002</td><td align="left">7.9 (1.0–64.4), p = 0.055*</td><td align="left">1.1 (0.5–2.4), p = 0.742</td></tr><tr><td align="left">Topical steroid</td><td align="left">6.0 (130)</td><td align="left">3.3 (224)</td><td align="left">p &lt; 0.001</td><td align="left">2.0 (1.3–3.1), p = 0.002*</td><td align="left">1.5 (1.1–2.0), p = 0.014</td></tr><tr><td align="left">Methotrexate</td><td align="left">15.3 (333)</td><td align="left">13.6 (937)</td><td align="left">p = 0.056</td><td align="left">1.5 (1.2–1.9), p &lt; 0.001*</td><td align="left">0.8 (0.7–1.0), p = 0.003</td></tr><tr><td align="left">Mycophenolate mofetil</td><td align="left">1.88 (41)</td><td align="left">5.16 (356)</td><td align="left">p &lt; 0.001</td><td align="left">1.7 (1.2–2.5), p = 0.004</td><td align="left">0.6 (0.4–0.7), p &lt; 0.001</td></tr><tr><td align="left">Adalimumab</td><td align="left">7.22 (495)</td><td align="left">10.02 (218)</td><td align="left">p &lt; 0.001</td><td align="left">1.5 (1.2–1.9), p = 0.001</td><td align="left">0.9 (0.7–1.0), p = 0.131</td></tr><tr><td align="left">Bevacizumab</td><td align="left">0.23 (5)</td><td align="left">1.27 (87)</td><td align="left">p &lt; 0.001</td><td align="left">1.1 (0.5–2.3), p = 0.888</td><td align="left">0.2 (0.1–0.4), p &lt; 0.001</td></tr><tr><td align="left">Rituximab</td><td align="left">0.09 (2)</td><td align="left">1.15 (79)</td><td align="left">p &lt; 0.001</td><td align="left">0.7 (0.4–1.3), p = 0.247</td><td align="left">0.2 (0.1–0.5), p &lt; 0.001</td></tr><tr><td align="left">Infliximab<hr/></td><td align="left">3.81 (83)<hr/></td><td align="left">5.25 (360)<hr/></td><td align="left">p = 0.007<hr/></td><td align="left">1.3 (0.9–1.7), p = 0.118<hr/></td><td align="left">0.7 (0.6–0.9), p = 0.019<hr/></td></tr><tr><td align="left">TOTAL</td><td align="left">100 (2176)</td><td align="left">100 (6855)</td><td/><td/><td/></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="sec3.7">
      <label>3.7</label>
      <title>Sentiment analysis with OcIMIDo</title>
      <p id="p0140">The TextBlob and VADER methods yielded very different median sentiment scores in the full combined dataset, of 0.12 (IQR 0.01–0.24) and 0.77 (0.08–0.93), respectively. The median TextBlob sentiment score was 0.10 (IQR 0 to 0.20) for the 2176 OV posts, and 0.13 (IQR 0.02 to 0.25) for the 6855 UVE posts, with sentiment scores ranging from −1.00 (most negative language) to +1.00 (most positive language). The median VADER sentiment score was 0.69 (IQR 0 to 0.91) for OV posts, and 0.79 (IQR 0.15 to 0.94) for UVE posts. <xref rid="fig2" ref-type="fig">Fig. 2</xref> shows the TextBlob sentiment scores associated with posts mentioning an illustrative selection of different classes (and their synonyms) within the ontology. Using 50% of the data from each forum, after splitting into quartiles of TextBlob and VADER scores, separately, we compared the AUC for the multivariable models of the odds of a post expressing a negative sentiment using either TextBlob (AUC = 0.64, n = 4480 posts) or VADER (AUC = 0.65, n = 4557 posts), see <xref rid="tbl2" ref-type="table">Table 2</xref>.<fig id="fig2"><label>Fig. 2</label><caption><p>Box plots illustrating spread of natural language sentiment scores with TextBlob for a range of clinical phenotypes, complications, systemic non-infectious diseases, and systemic treatments, combining data from Olivia's Vision and The Ocular Immunology and Uveitis Foundation fora. The scores for each class (including synonyms) ranged from −1.00 (most negative language) to +1.00 (most positive language).</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p>
      <p id="p0145">In both multivariable models the odds of a post expressing negative (25th percentile) language sentiment were significantly associated with the first post in a thread, compared to replies (OR 3.3, 95% CI 2.8 to 3.9, p &lt; 0.001 for TextBlob and OR 3.3, 95% CI 2.9 to 3.9, p &lt; 0.001 for VADER), and posts mentioning treatment with oral prednisolone (OR 2.2, 95% CI 1.5–3.4, p &lt; 0.001 for TextBlob, OR 1.3, 95% CI 1.0 to 1.7, p &lt; 0.001 for VADER). In other respects, using data from these sentiment analysis tools, which yielded very different median scores, resulted in models with markedly differing significant associations with OcIMIDO class items. TextBlob median was closest to 0, whilst VADER scores near 1 indicating error towards a ceiling effect, this may be due to the data each were trained on or that VADER's method focuses on individual words and ignoring that word context in which it is used - due to this, we continue to report on sentiment using TextBlob.</p>
    </sec>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Discussion</title>
    <p id="p0150">We have reported the development and validation of a novel ontology for inflammatory eye disease, OcIMIDo (version 1.2). OcIMIDo organizes 661 classes into high-level concepts of diagnostic subtype, clinical features, classification (anatomy), disease activity, time course, core investigations, therapeutic interventions (and their efficacy and side effects), complications, and functional impacts, with structured knowledge representation. OcIMIDo joins only a small number of other disease area-specific ontologies currently available in general medicine. Notable examples include the @neurIST ontology of intracranial aneurysms [<xref rid="bib40" ref-type="bibr">40</xref>], and the ACGT Master Ontology of Cancer [<xref rid="bib41" ref-type="bibr">41</xref>]. <funding-source id="gs2">Furthermore</funding-source>, we have reported use of an NLP-guided method to identify patient-preferred terms for inclusion in the ontology under class clinical terms as synonyms from a public patient support forum. This addresses an unmet need to better align computational tools with patient and physician-preferred language [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib20" ref-type="bibr">20</xref>].</p>
    <p id="p0155">The OcIMIDo-based annotations confirmed that both of the patient online fora provide a space for patients to discuss a broad range of issues relating to inflammatory eye disease. The differences observed between the fora may relate to differences in the patient groups targeted; UVE is hosted by a USA-based charity and serves patients with a wide range of ocular inflammatory disorders including uveitis, optic neuritis and scleritis; OV is hosted by a UK-based charity catering especially to paediatric uveitis patients.</p>
    <p id="p0160">Sentiment analysis using both tools revealed that first posts were significantly more negative than replies. This provides some insight into the supportive role that online fora play for patients and their carers. The exploratory, multi-variable regression models had reasonable fit (AUC 0.64 and 0.65), given the lack of individual patient data. However, the multiple significant associations between the most negative 25% of post sentiment scores and various ontology classes differed comparing VADER and TextBlob, suggesting that these tools are not measuring sentiment in a concordant way. Manual review of posts and sentiment scores further indicated that sentiment analysis at the level of an entire post provided only limited insight; individual posts frequently contained discussion of a number of disease presentations and treatments (multiple ontology classes), with both positive and negative language sentiments expressed in relation to these.</p>
    <p id="p0165">By illustrating that OcIMIDo, used alongside NLP approaches, facilitates standardised extraction for analysis of real-world unstructured big data in the form of online patient forum posts, we hope to have highlighted how quantitative data can be obtained from this valuable, untapped patient-reported resource. There is increasingly urgent recognition of the need to better understand and integrate the ‘patient voice’ in clinical care pathways, research priority setting, and the development of meaningful outcome measure [<xref rid="bib1" ref-type="bibr">1</xref>]. We propose that patient support fora could play a particularly helpful role in identifying issues of concern, and advancing patient-centred care for rarer diseases.</p>
    <sec id="sec4.1">
      <label>4.1</label>
      <title>Implications</title>
      <p id="p0170">OcIMIDo is freely available to the community as an open source tool, via GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/sap218/ocimido" id="intref0015">https://github.com/sap218/ocimido</ext-link>). The classes in OcIMIDo were largely uncovered by existing biomedical ontologies (see <xref rid="appsec1" ref-type="sec">Supplementary Table 5</xref>). Furthermore, OcIMIDo provides an implicit axiomatic structure for data annotated with SNOMED-CT [<xref rid="bib19" ref-type="bibr">19</xref>], ICD-10 [<xref rid="bib17" ref-type="bibr">17</xref>], or Read codes [<xref rid="bib18" ref-type="bibr">18</xref>], as these are included as cross-references in the ontology. This enhances the potential value of OcIMIDo for searching and curating unstructured clinical data. Clinician researchers in other medical specialties, such as rheumatology, gastroenterology, infectious disease, and neurology, may find OcIMIDo a useful resource to use, for advancing the understanding of the inflammatory ocular manifestations of the systemic diseases they manage.</p>
      <p id="p0175">Our study revealed that two commonly used sentiment analysis tools, TextBlob and VADER, yielded very different sentiment scores. Further work is needed to explore the possible reasons for this. Developing OcIMIDo was part of a wider program of work by our group, which includes the development of a semantic framework to fully capture health-related quality of life (QoLo). In future research, our team aims to conduct more advanced applications of OcIMIDo and QoLo together, to improve our understanding of the impacts of inflammatory eye disease and its treatment on patients, and to identify novel content for inclusion in patient reported outcome measures, thereby helping to overcome one of the key barriers to their development.</p>
      <p id="p0180">In a future revision and expansion of OcIMIDo, beyond the currently defined robust relationships, we aim to include an expanded set of classes and axioms relating to evidence-based investigations, risk factors, symptoms, and their inter-relationships, and more extensive cross-references to SNOMED-CT, Read codes and the soon-to-be adopted ICD-11. We will also consider further classifying synonyms as exact (precise alternatives), narrow (more specific), broad (general), or related (associated terms). The value of more descriptive axiomatisation is that it will further enable ontology-based analysis techniques, such as semantic similarity, which can be used to risk stratify patients [<xref rid="bib42" ref-type="bibr">42</xref>]. OcIMIDo could be further expanded to include additional inflammatory and infectious IMIDs associated with other neuro-ophthalmic, corneal, orbital and adnexal disease presentations. We could add synonyms identified from additional online patient support groups internationally for different ocular and systemic IMIDs. Further potential applications include exploring clinical phenotypes and genetic phenotypes in biobank databases [<xref rid="bib43" ref-type="bibr">43</xref>], text-mining both open source and EHR data, performing cluster analysis to study underlying relationships in patients with a given disease, and developing ontology-guided predictive algorithms [<xref rid="bib7" ref-type="bibr">7</xref>].</p>
    </sec>
    <sec id="sec4.2">
      <label>4.2</label>
      <title>Limitations</title>
      <p id="p0185">This study has a number of limitations. Firstly, in relation to the ontology development, the Royal College of Ophthalmology consensus document used as the ontology foundation lacked detail on relationships [<xref rid="bib27" ref-type="bibr">27</xref>]. In addition, a small number of clinical specialists with domain expertise were involved in the development of version 1.2. As we, and other research teams in the community, make use of this free, open access tool, we anticipate that OcIMIDo will be further revised and expanded, with user suggestions and changes being publicly visible and tracked on the repository's “issues” tab. Secondly, as a data resource, unstructured text has multiple limitations. Spell-checking modules in Python do not recognise many terms (e.g. drugs) which we curated as synonyms. In future updates, low-count tf-idf terms, which were misspelled, could potentially be addressed by distance measure techniques. Moreover other synonym curation techniques, such as word2vec, could be considered as they capture semantic similarity in terms of vectors, we did not consider using these techniques as they don't capture the whole document and all terms in terms of rank: the tf-idf and word2vec methods would not be directly comparable - other techniques would be future endeavours. Thirdly, a limitation of using natural language sentiment analysis to illustrate an application of the ontology, was that since the unit of analysis was online posts, extracted retrospectively and without reference to user names, posts may not have been independent (i.e. one patient/carer may have posted/replied on multiple occasions). Additionally labelling the forum is a time-consuming task and there is a lack of publicly labelled patient forum conversation to develop a ML model, so we used pretrained models, in future we would explore developing a trained model. The emergent clinical phenotypes suggested for each forum should therefore be interpreted cautiously, as should the modelled associations between class terms and sentiment scores, which were purely exploratory.</p>
      <p id="p0190">It is important to highlight that ontologies are only part of the solution to extracting structured data from unstructured text. OcIMIDo must be used with other NLP computational tools to annotate text data, and manual review may still play an important role. We have illustrated the simple instantiation of ontology classes in an unstructured dataset, but additional tools will be needed for more nuanced analysis [<xref rid="bib44" ref-type="bibr">44</xref>]. For example, a given class term, such as ‘methotrexate, might be mentioned in different contexts, such as, ‘history of methotrexate use’, ‘current methotrexate use’, ‘allergy to methotrexate’, or ‘no prior methotrexate use’. Stanford CoreNLP provides context disambiguation tools to help address this by determining information such as bearer (who the mention refers to), temporal status, negation, and uncertainty.</p>
    </sec>
    <sec id="sec4.3">
      <label>4.3</label>
      <title>Conclusions</title>
      <p id="p0195">We have demonstrated that the development of an ontology for a specific disease area, enriched with patient-preferred synonyms, provides a potential solution to the challenges arising from the expanding volume of valuable but unstructured patient-reported text data, and the differences between patients' and clinicians' vocabularies and terminologies. Our approach to developing and validating an ontology, using online patient support fora as a data source to permit incorporation of the ‘patient voice’, is readily applicable to other areas of medicine.</p>
    </sec>
  </sec>
  <sec id="sec5">
    <title>Ethics statement</title>
    <p id="p0200">The University of Birmingham Ethics Committee determined that approval was not required for this study (ERN_20-0047). The research adhered to the tenets of the Declaration of Helsinki.</p>
  </sec>
  <sec sec-type="data-availability" id="sec6">
    <title>Data availability</title>
    <p id="p0205">Yes - all data are fully available without restriction.</p>
    <p id="p0210">The corresponding author confirms that they had full access to all the data in the study and had final responsibility for the decision to submit for publication. Online forum textual data collected is already publicly available - users are able to access without credentials. We have made the ontology available at <ext-link ext-link-type="uri" xlink:href="https://github.com/sap218/ocimido" id="intref0100">https://github.com/sap218/ocimido</ext-link> via a creative commons license (CC 3.0).</p>
  </sec>
  <sec id="sec7">
    <title>Financial disclosure</title>
    <p id="p0215">SCP and GVG acknowledge support from the <funding-source id="gs3">Medical Research Council</funding-source> (MR/S502431/1) that directly funded this work (<ext-link ext-link-type="uri" xlink:href="https://mrc.ukri.org/" id="intref0020">https://mrc.ukri.org/</ext-link>).</p>
    <p id="p0220">LTS and GVG also acknowledge support from <funding-source id="gs4">Horizon 2020 E-Infrastructures</funding-source> (H2020-EINFRA) (731075) (<ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/programmes/horizon2020/en" id="intref0025">https://ec.europa.eu/programmes/horizon2020/en</ext-link>) in addition to NanoCommons (H2020-EU) (731032) (<ext-link ext-link-type="uri" xlink:href="https://www.nanocommons.eu/" id="intref0030">https://www.nanocommons.eu/</ext-link>).</p>
    <p id="p0225">AK was supported by the <funding-source id="gs6">Medical Research Council</funding-source> (MR/S003991/1) (<ext-link ext-link-type="uri" xlink:href="https://mrc.ukri.org/" id="intref0035">https://mrc.ukri.org/</ext-link>).</p>
    <p id="p0230">RMG, GVG, and AKD acknowledge support from the <funding-source id="gs7">Health Data Research UK</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://www.hdruk.ac.uk/" id="intref0040">https://www.hdruk.ac.uk/</ext-link>), GVG being directly funded (HDRUK/CFC/01).</p>
    <p id="p0235">GVG acknowledges support from the <funding-source id="gs8">National Institute for Health Research</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://www.nihr.ac.uk/" id="intref0045">https://www.nihr.ac.uk/</ext-link>) <funding-source id="gs9">Birmingham Experimental Cancer Medicine Centres</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://www.ecmcnetwork.org.uk/" id="intref0050">https://www.ecmcnetwork.org.uk/</ext-link>), <funding-source id="gs10">NIHR Birmingham Surgical Reconstruction</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://www.birminghambrc.nihr.ac.uk/" id="intref0055">https://www.birminghambrc.nihr.ac.uk/</ext-link>) and <funding-source id="gs11">Microbiology Research Centre</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://srmrc.nihr.ac.uk/" id="intref0060">https://srmrc.nihr.ac.uk/</ext-link>), and the <funding-source id="gs12">NIHR Birmingham Biomedical Research Centre</funding-source> (<ext-link ext-link-type="uri" xlink:href="https://www.uclh.nhs.uk/Research/BRC/Pages/Home.aspx" id="intref0065">https://www.uclh.nhs.uk/Research/BRC/Pages/Home.aspx</ext-link>).</p>
    <p id="p0240">TB was part-funded for clinical research by patient charity Olivia’s Vision (<ext-link ext-link-type="uri" xlink:href="http://www.oliviasvision.org/" id="intref0070">http://www.oliviasvision.org/</ext-link>).</p>
    <p id="p0245">The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
  </sec>
  <sec id="sec8">
    <title>CRediT authorship contribution statement</title>
    <p id="p0250"><bold>Samantha C Pendleton:</bold> Data curation, Methodology, Software, Writing - Original draft preparation. <bold>Karin Slater:</bold> Conceptualization of this study, Methodology, Writing - Original draft preparation. <bold>Andreas Karwath:</bold> Data curation, Methodology, Writing - Original draft preparation. <bold>Rose M Gilbert:</bold> Methodology, Writing - Original draft preparation. <bold>Konrad Pesudovs:</bold> Writing - Original draft preparation. Xiaoxuan Liu: Methodology, Writing - Original draft preparation. <bold>Alastair K Denniston:</bold> Conceptualization of this study, Writing - Original draft preparation. <bold>Georgios V Gkoutos:</bold> Conceptualization of this study, Writing - Original draft preparation. <bold>Tasanee Braithwaite:</bold> Conceptualization of this study, Methodology, Software, Writing - Original draft preparation.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of competing interest</title>
    <p id="p0255">The authors have declared that no competing interests exist.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Dean</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Mathers</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Calvert</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kyte</surname>
            <given-names>D.G.</given-names>
          </name>
          <name>
            <surname>Conroy</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Folkard</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Southworth</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>P.I.</given-names>
          </name>
          <name>
            <surname>Denniston</surname>
            <given-names>A.K.</given-names>
          </name>
        </person-group>
        <article-title>The patient is speaking”: discovering the patient voice in ophthalmology</article-title>
        <source>Br. J. Ophthalmol.</source>
        <volume>101</volume>
        <year>June 2017</year>
        <fpage>700</fpage>
        <lpage>708</lpage>
        <pub-id pub-id-type="pmid">28455280</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Hoehndorf</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Schofield</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Gkoutos</surname>
            <given-names>G.V.</given-names>
          </name>
        </person-group>
        <article-title>The role of ontologies in biological and biomedical research: a functional perspective</article-title>
        <source>Briefings Bioinf.</source>
        <volume>16</volume>
        <year>Nov. 2015</year>
        <fpage>1069</fpage>
        <lpage>1080</lpage>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Haendel</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Chute</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
        </person-group>
        <article-title>Classification, ontology, and precision medicine</article-title>
        <source>N. Engl. J. Med.</source>
        <volume>379</volume>
        <year>Oct. 2018</year>
        <fpage>1452</fpage>
        <lpage>1462</lpage>
        <pub-id pub-id-type="pmid">30304648</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Aldosari</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Alanazi</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Househ</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Pitfalls of ontology in medicine</article-title>
        <source>Stud. Health Technol. Inf.</source>
        <volume>238</volume>
        <year>2017</year>
        <fpage>15</fpage>
        <lpage>18</lpage>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Gruber</surname>
            <given-names>T.R.</given-names>
          </name>
        </person-group>
        <article-title>Toward principles for the design of ontologies used for knowledge sharing?</article-title>
        <source>Int. J. Hum. Comput. Stud.</source>
        <volume>43</volume>
        <year>Nov. 1995</year>
        <fpage>907</fpage>
        <lpage>928</lpage>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Gkoutos</surname>
            <given-names>G.V.</given-names>
          </name>
          <name>
            <surname>Schofield</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Hoehndorf</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>The anatomy of phenotype ontologies: principles, properties and applications</article-title>
        <source>Briefings Bioinf.</source>
        <volume>19</volume>
        <year>Sept. 2018</year>
        <fpage>1008</fpage>
        <lpage>1021</lpage>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Min</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Mobahi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Irvin</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Avramovic</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wojtusiak</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Predicting activities of daily living for cancer patients using an ontology-guided machine learning methodology</article-title>
        <source>J. Biomed. Semant.</source>
        <volume>8</volume>
        <issue>39</issue>
        <year>Sept. 2017</year>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="book" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bittner</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <part-title>Basic Formal Ontology for Bioinformatics</part-title>
        <year>2005</year>
        <publisher-name>IFOMIS Reports</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Schriml</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Arze</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Nadendla</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>Y.-W.W.</given-names>
          </name>
          <name>
            <surname>Mazaitis</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Felix</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Kibbe</surname>
            <given-names>W.A.</given-names>
          </name>
        </person-group>
        <article-title>Disease ontology: a backbone for disease semantic integration</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>40</volume>
        <year>Jan. 2012</year>
        <fpage>D940</fpage>
        <lpage>D946</lpage>
        <pub-id pub-id-type="pmid">22080554</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Köhler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Seelow</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Horn</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Mundlos</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>The human phenotype ontology: a tool for annotating and analyzing human hereditary disease</article-title>
        <source>Am. J. Hum. Genet.</source>
        <volume>83</volume>
        <year>Nov. 2008</year>
        <fpage>610</fpage>
        <lpage>615</lpage>
        <pub-id pub-id-type="pmid">18950739</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Köhler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Carmody</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Vasilevsky</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>J.O.B.</given-names>
          </name>
          <name>
            <surname>Danis</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gourdine</surname>
            <given-names>J.-P.</given-names>
          </name>
          <name>
            <surname>Gargano</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>N.L.</given-names>
          </name>
          <name>
            <surname>Matentzoglu</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>McMurry</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Osumi-Sutherland</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Cipriani</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Balhoff</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Conlin</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Blau</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Baynam</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Palmer</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Gratian</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Dawkins</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Segal</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Jansen</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Muaz</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>W.H.</given-names>
          </name>
          <name>
            <surname>Bergerson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Laulederkind</surname>
            <given-names>S.J.F.</given-names>
          </name>
          <name>
            <surname>Yüksel</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Beltran</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Freeman</surname>
            <given-names>A.F.</given-names>
          </name>
          <name>
            <surname>Sergouniotis</surname>
            <given-names>P.I.</given-names>
          </name>
          <name>
            <surname>Durkin</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Storm</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Hanauer</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Brudno</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bello</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Sincan</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rageth</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Oegema</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Lourghi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Della Rocca</surname>
            <given-names>M.G.</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Castellanos</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Priest</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Hegde</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lovering</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Hajek</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Olry</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Notarangelo</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Similuk</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.A.</given-names>
          </name>
          <name>
            <surname>Gómez-Andrés</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Lochmüller</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Dollfus</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Rosenzweig</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Marwaha</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Rath</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Milner</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Leroux</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Boerkoel</surname>
            <given-names>C.F.</given-names>
          </name>
          <name>
            <surname>Klion</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>M.C.</given-names>
          </name>
          <name>
            <surname>Groza</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Smedley</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Haendel</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
        </person-group>
        <article-title>Expansion of the human phenotype ontology (HPO) knowledge base and resources</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>47</volume>
        <year>Jan. 2019</year>
        <fpage>D1018</fpage>
        <lpage>D1027</lpage>
        <pub-id pub-id-type="pmid">30476213</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Sergouniotis</surname>
            <given-names>P.I.</given-names>
          </name>
          <name>
            <surname>Maxime</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Leroux</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Olry</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Rath</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Dollfus</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>ERN-EYE Ontology Study Group</surname>
          </name>
        </person-group>
        <article-title>An ontological foundation for ocular phenotypes and rare eye diseases</article-title>
        <source>Orphanet J. Rare Dis.</source>
        <volume>14</volume>
        <issue>8</issue>
        <year>Jan. 2019</year>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="book" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Vasant</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Chanas</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hanauer</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Olry</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Jupp</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Parkinson</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Rath</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <part-title>Ordo: an ontology connecting rare disease, epidemiology and genetic data</part-title>
        <source>Proceedings of ISMB</source>
        <volume>vol. 30</volume>
        <year>2014</year>
        <publisher-name>researchgate.net</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ceusters</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Klagges</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Köhler</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lomax</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Neuhaus</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Rector</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Rosse</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Relations in biomedical ontologies</article-title>
        <source>Genome Biol.</source>
        <volume>6</volume>
        <year>Apr. 2005</year>
        <fpage>R46</fpage>
        <pub-id pub-id-type="pmid">15892874</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Mungall</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Torniai</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Gkoutos</surname>
            <given-names>G.V.</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>Haendel</surname>
            <given-names>M.A.</given-names>
          </name>
        </person-group>
        <article-title>Uberon, an integrative multi-species anatomy ontology</article-title>
        <source>Genome Biol.</source>
        <volume>13</volume>
        <year>Jan. 2012</year>
        <fpage>R5</fpage>
        <pub-id pub-id-type="pmid">22293552</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Bodenreider</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>The unified medical language system (UMLS): integrating biomedical terminology</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>32</volume>
        <year>Jan. 2004</year>
        <fpage>D267</fpage>
        <lpage>D270</lpage>
        <pub-id pub-id-type="pmid">14681409</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="book" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>World Health Organization</surname>
          </name>
        </person-group>
        <part-title>International Classification of Diseases (ICD)</part-title>
        <year>2006</year>
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/classifications/icd/en/" id="intref0080">http://www.who.int/classifications/icd/en/</ext-link>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Benson</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>The history of the read codes: the inaugural james read memorial lecture 2011</article-title>
        <source>Inf. Prim. Care</source>
        <volume>19</volume>
        <issue>3</issue>
        <year>2011</year>
        <fpage>173</fpage>
        <lpage>182</lpage>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Cornet</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>de Keizer</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Forty years of SNOMED: a literature review</article-title>
        <source>BMC Med. Inf. Decis. Making</source>
        <volume>8</volume>
        <issue>Suppl 1</issue>
        <year>Oct. 2008</year>
        <fpage>S2</fpage>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="book" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Vasilevsky</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Engelstad</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Foster</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>P.N.</given-names>
          </name>
          <name>
            <surname>Köhler</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Haendel</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <part-title>Enhancing the human phenotype ontology for use by the layperson</part-title>
        <source>ICBO/BioCreative</source>
        <volume>vol. 5</volume>
        <year>Apr. 2016</year>
        <publisher-name>F1000Research</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="book" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <part-title>Automatic synonym extraction using Word2Vec and spectral clustering</part-title>
        <source>2017 36th Chinese Control Conference (CCC)</source>
        <year>July 2017</year>
        <fpage>5629</fpage>
        <lpage>5632</lpage>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Braithwaite</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Petzold</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Galloway</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Adderley</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Mollan</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Plant</surname>
            <given-names>G.T.</given-names>
          </name>
          <name>
            <surname>Nirantharakumar</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Denniston</surname>
            <given-names>A.K.</given-names>
          </name>
        </person-group>
        <article-title>Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease</article-title>
        <source>JAMA Neurol.</source>
        <volume>77</volume>
        <year>Dec. 2020</year>
        <fpage>1514</fpage>
        <lpage>1523</lpage>
        <pub-id pub-id-type="pmid">33017023</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Braithwaite</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Adderley</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Galloway</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kempen</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Gokhale</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Cope</surname>
            <given-names>A.P.</given-names>
          </name>
          <name>
            <surname>Dick</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Nirantharakumar</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Denniston</surname>
            <given-names>A.K.</given-names>
          </name>
        </person-group>
        <article-title>Epidemiology of scleritis in the United Kingdom from 1997 to 2018: population-based analysis of 11 million patients and association between scleritis and infectious and immune-mediated inflammatory disease</article-title>
        <source>Arthritis rheumatol.</source>
        <year>Mar. 2021</year>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Al-Ani</surname>
            <given-names>H.H.</given-names>
          </name>
          <name>
            <surname>Sims</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Tomkins-Netzer</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Lightman</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Niederer</surname>
            <given-names>R.L.</given-names>
          </name>
        </person-group>
        <article-title>Vision loss in anterior uveitis</article-title>
        <source>Br. J. Ophthalmol.</source>
        <volume>104</volume>
        <year>Apr. 2020</year>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Musen</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Protégé Team</surname>
          </name>
        </person-group>
        <article-title>The protégé project: a look back and a look forward</article-title>
        <source>AI Matters</source>
        <volume>1</volume>
        <year>June 2015</year>
        <fpage>4</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="pmid">27239556</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>McGuinness</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Van Harmelen</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Others</surname>
          </name>
        </person-group>
        <article-title>OWL web ontology language overview</article-title>
        <source>W3C recommendation</source>
        <volume>10</volume>
        <issue>10</issue>
        <year>2004</year>
        <fpage>2004</fpage>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Denniston</surname>
            <given-names>A.K.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>R.W.</given-names>
          </name>
          <name>
            <surname>Pavesio</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Stanford</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>P.I.</given-names>
          </name>
          <name>
            <surname>Okada</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sen</surname>
            <given-names>H.N.</given-names>
          </name>
          <name>
            <surname>Dick</surname>
            <given-names>A.D.</given-names>
          </name>
        </person-group>
        <article-title>Uveitis dataset clinical dataset</article-title>
        <source>tech. rep., The Royal College of Ophthalmologists</source>
        <year>Oct. 2018</year>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Côté</surname>
            <given-names>R.G.</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Apweiler</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Hermjakob</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>The ontology lookup service, a lightweight cross-platform tool for controlled vocabulary queries</article-title>
        <source>BMC Bioinf.</source>
        <volume>7</volume>
        <year>Feb. 2006</year>
        <fpage>97</fpage>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="book" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>van Rossum</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <part-title>Python tutorial, technical report CS-R9526</part-title>
        <source>Centrum voor Wiskunde en Informatica</source>
        <year>1995</year>
        <publisher-name>CWI)</publisher-name>
        <publisher-loc>Amsterdam</publisher-loc>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="book" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Bird</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Loper</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <part-title>Natural Language Processing with Python: Analyzing Text with the Natural Language Toolkit</part-title>
        <year>June 2009</year>
        <publisher-name>“O'Reilly Media, Inc.”</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Pedregosa</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Varoquaux</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Gramfort</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Michel</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Thirion</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Grisel</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Blondel</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Prettenhofer</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Weiss</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Dubourg</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Vanderplas</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Passos</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cournapeau</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Brucher</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Perrot</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Duchesnay</surname>
            <given-names>É.</given-names>
          </name>
        </person-group>
        <article-title>Scikit-learn: machine learning in python</article-title>
        <source>J. Mach. Learn. Res.</source>
        <volume>12</volume>
        <issue>Oct</issue>
        <year>2011</year>
        <fpage>2825</fpage>
        <lpage>2830</lpage>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="book" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Manning</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Surdeanu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Finkel</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bethard</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McClosky</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <part-title>The stanford CoreNLP natural language processing toolkit</part-title>
        <source>Proceedings of 52nd Annual Meeting of the Association for Computational Linguistics: System Demonstrations</source>
        <year>2014</year>
        <fpage>55</fpage>
        <lpage>60</lpage>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="book" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Loria</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <part-title><italic>Textblob</italic> Documentation</part-title>
        <comment>Technical report</comment>
        <year>2018</year>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="book" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Lane</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hapke</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Howard</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <part-title>Natural Language Processing in Action: Understanding, Analyzing, and Generating Text with Python</part-title>
        <year>Apr. 2019</year>
        <publisher-name>Manning Publications</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bastola</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Utilizing twitter data for analysis of chemotherapy</article-title>
        <source>Int. J. Med. Inform.</source>
        <volume>120</volume>
        <year>Dec. 2018</year>
        <fpage>92</fpage>
        <lpage>100</lpage>
        <pub-id pub-id-type="pmid">30409350</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Davidson</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Warmsley</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Macy</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>I.</given-names>
          </name>
        </person-group>
        <article-title>Automated hate speech detection and the problem of offensive language</article-title>
        <source>ICWSM</source>
        <volume>11</volume>
        <year>May 2017</year>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="book" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>StataCorp</surname>
            <given-names>L.P.</given-names>
          </name>
          <etal/>
        </person-group>
        <part-title>Stata Statistical Software</part-title>
        <comment>College Station TX</comment>
        <year>2009</year>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Matentzoglu</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Stevens</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>MIRO: guidelines for minimum information for the reporting of an ontology</article-title>
        <source>J. Biomed. Semant.</source>
        <volume>9</volume>
        <issue>6</issue>
        <year>Jan. 2018</year>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Lohmann</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Negru</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Haag</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Ertl</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Visualizing ontologies with VOWL</article-title>
        <source>Semantic Web</source>
        <volume>7</volume>
        <issue>4</issue>
        <year>2016</year>
        <fpage>399</fpage>
        <lpage>419</lpage>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Boeker</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Stenzhorn</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Kumpf</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Bijlenga</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Schulz</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Hanser</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>The @neurIST ontology of intracranial aneurysms: providing terminological services for an integrated IT infrastructure</article-title>
        <source>AMIA Annu. Symp. Proc.</source>
        <year>Oct. 2007</year>
        <fpage>56</fpage>
        <lpage>60</lpage>
        <pub-id pub-id-type="pmid">18693797</pub-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Brochhausen</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Spear</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Cocos</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Weiler</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Martín</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Anguita</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Stenzhorn</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Daskalaki</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Schera</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Schwarz</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Sfakianakis</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kiefer</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Dörr</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Graf</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Tsiknakis</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The ACGT master ontology and its applications–towards an ontology-driven cancer research and management system</article-title>
        <source>J. Biomed. Inf.</source>
        <volume>44</volume>
        <year>Feb. 2011</year>
        <fpage>8</fpage>
        <lpage>25</lpage>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>42</label>
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Greene</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>NIHR BioResource</surname>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Turro</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Phenotype similarity regression for identifying the genetic determinants of rare diseases</article-title>
        <source>Am. J. Hum. Genet.</source>
        <volume>98</volume>
        <year>Mar. 2016</year>
        <fpage>490</fpage>
        <lpage>499</lpage>
        <pub-id pub-id-type="pmid">26924528</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <label>43</label>
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Sudlow</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Gallacher</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Beral</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Burton</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Danesh</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Downey</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Elliott</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Landray</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Matthews</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Ong</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Pell</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Silman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sprosen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Peakman</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>
        <source>PLoS Med.</source>
        <volume>12</volume>
        <year>Mar. 2015</year>
        <comment>e1001779</comment>
      </element-citation>
    </ref>
    <ref id="bib44">
      <label>44</label>
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Stenzhorn</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Schulz</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Boeker</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>Adapting clinical ontologies in Real-World environments</article-title>
        <source>J. Univers. Comput. Sci.</source>
        <volume>14</volume>
        <issue>22</issue>
        <year>2008</year>
        <fpage>3767</fpage>
        <lpage>3780</lpage>
        <pub-id pub-id-type="pmid">20390048</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec1" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0265">The following is the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia componenet 1</title></caption><media xlink:href="mmc1.pdf"><alt-text>Multimedia componenet 1</alt-text></media></supplementary-material></p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgements</title>
    <p id="p0260">We wish to thank the patient support charities, Olivia's Vision, and Professor Stephen Foster, on behalf of The Ocular Immunology and Uveitis Foundation, who kindly gave permission to access the foundation's public forum to be explored in this study.</p>
  </ack>
  <fn-group>
    <fn id="appsec2" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0270">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.compbiomed.2021.104542" id="intref0075">https://doi.org/10.1016/j.compbiomed.2021.104542</ext-link>.</p>
    </fn>
  </fn-group>
</back>
